Johnson & Johnson pays $181m for misleading marketing of risperidoneBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e5916 (Published 03 September 2012) Cite this as: BMJ 2012;345:e5916
- Janice Hopkins Tanne
- 1New York
New York state’s attorney general, Eric Schneiderman, announced on 29 August a $181m (£114m; €144m) settlement with Janssen Pharmaceuticals and its parent company, Johnson & Johnson, for deceptive marketing of its antipsychotic drug risperidone (marketed as Risperdal) and some related drugs.
The settlement involved the attorneys general of 36 other states and the District of Columbia. New York will receive about $9m in the settlement.
Doctors may prescribe any drug approved by the FDA for any condition for which they believe it may be helpful. However, Schneiderman …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial